Gilead Sciences (GILD) Net Margin Growth (3y) (2012 - 2026)
Powered by 
Analysis
Gilead Sciences (GILD) Net Margin Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 388.00 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -15,026.00 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -374.00 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -44.00 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 6,620.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -13,815.00 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 9,934.00 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -2,059.00 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -1.86 Mn |
| 10 | Insmed | 27.67 Bn | 26.51 Bn | 358.27 Mn | 31,387.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15,026.00 |
| Mar 31, 2026 | 1,355.00 |
| Dec 31, 2025 | 980.00 |
| Sep 30, 2025 | 1,392.00 |
| Jun 30, 2025 | 956.00 |
| Mar 31, 2025 | 1,954.00 |
| Dec 31, 2024 | 1,835.00 |
| Sep 30, 2024 | -1,824.00 |
| Jun 30, 2024 | -118.00 |
| Mar 31, 2024 | -8,919.00 |
| Dec 31, 2023 | -90.00 |
| Sep 30, 2023 | 2,544.00 |
| Jun 30, 2023 | 8,080.00 |
| Mar 31, 2023 | -1,223.00 |
| Dec 31, 2022 | 1,018.00 |
| Sep 30, 2022 | 4,620.00 |
| Jun 30, 2022 | -1,485.00 |
| Mar 31, 2022 | -3,708.00 |
| Dec 31, 2021 | -220.00 |
| Sep 30, 2021 | -266.00 |